← Leaderboards
Michael Shabot
La Biomed Res Inst/ Harbor Ucla Med Ctr
$238,960
Attributed
$238,960
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$238,960 · 2
By mechanism
M01$238,960 · 2
Top collaborators
No co-investigators on record.
Most similar at La Biomed Res Inst/ Harbor Ucla Med Ctr
Same institution · by research overlap
- Michael Agus$11,475,515
- Yutaka Niihara$901,548
- Margaret A Keller$2,116,833
- Ronald Sherwin Swerdloff$7,352,119
- Emil Dennis Kakkis$2,211,272
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationErythropoietinBlood TransfusionIntensive CareInflammationClinical TrialsBacterial DiseaseBlood Disorder ChemotherapyBlood ToxicologyAntibacterial AgentsDrug Screening /Evaluation
Grant awards (5)
RANDOMIZED PLACEBO CONTROLLED TRIAL OF MAK195K IN SEPSIS WITH HYPERINFLAMMATION$237,978
M01 · FY2001 · RR
RANDOMIZED PLACEBO CONTROLLED TRIAL OF MAK195K IN SEPSIS WITH HYPERINFLAMMATION$982
M01 · FY2000 · RR
Efficacy of rHuEPO in the critically ill patient$0
M01 · FY2000 · RR
Efficacy of rHuEPO in the critically ill patient$0
M01 · FY2000 · RR
Efficacy of rHuEPO in the critically ill patient$0
M01 · FY2000 · RR